non-alcoholic steatohepatitis
Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients
June 8, 2023Medical Education Echosens, Hepatology, Inventiva, liver disease, nash, non-alcoholic steatohepatitis
French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens to bring attention to, and …
Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis
November 11, 2019Research and Development, Sales and Marketing Novartis, nash, non-alcoholic steatohepatitis, pharma
The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR …
Intercept’s NASH liver fibrosis drug shows promise at Phase 3
February 20, 2019Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma
Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
